皮下免疫グロブリン市場：適応症別、エンドユーザー別-2025-2030年の世界予測

皮下免疫グロブリン市場は、2023年に94億7,000万米ドルと評価され、2024年には104億6,000万米ドルに達すると予測され、CAGR 10.82％で成長し、2030年には194億6,000万米ドルになると予測されています。

皮下免疫グロブリン（SCIg）とは、皮下注射による免疫グロブリンの投与を含む医療療法を指し、主に原発性免疫不全症や特定の自己免疫疾患の患者に適用されます。その必要性は、免疫系が低下した患者の感染症対策に不可欠な免疫グロブリンレベルを適切に維持する必要性から生じています。その適用範囲は、静脈内投与に比べ患者の利便性が高い通常の在宅輸液から、主に免疫不全患者を対象とする病院環境まで多岐にわたる。最終用途には、ヘルスケア施設、在宅ケア環境、専門クリニックなどが含まれます。市場成長は、免疫不全疾患の有病率の上昇、SCIg製剤の進歩、在宅治療に対する患者の嗜好の高まりに大きく影響されています。さらに、現在進行中の研究開発により、無針システムなどの革新的な送達メカニズムが生み出され、市場の注目を集めています。しかし、潜在的な副作用、高額な治療費、規制上の課題といった制約があり、これが市場の成長を妨げる可能性があります。さらに、治療オプションに関する患者の意識は地域によって一貫しておらず、これが課題をさらに大きくしています。最近の潜在的なビジネスチャンスとしては、SCIgの新たな治療領域への応用拡大や、未開拓市場への販売網の強化などが挙げられます。このような機会を捉えるための推奨事項としては、教育・啓発プログラムへの投資、ヘルスケアプロバイダーとの提携、有利な償還政策への働きかけなどが挙げられます。送達デバイスの改良や、より安定した免疫グロブリン製剤の処方などの革新は、事業成長のための有望な研究分野です。さらに、患者のモニタリングと管理のためのデジタル・プラットフォームは、戦略的優位性をもたらす可能性があります。SCIg市場は、複数の主要企業が常に技術進歩に投資している競合情勢が特徴です。持続的な成長のために技術革新と治療革新に注力しながら、規制状況、患者擁護、競合情勢を乗り切る戦略的敏捷性が求められます。

市場力学：急速に進化する皮下免疫グロブリン市場の主要市場インサイトを公開

皮下免疫グロブリン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の自己免疫疾患の有病率の上昇
  • 適応外使用における皮下免疫グロブリンの使用量の増加
  • バイオテクノロジー企業や製薬企業による研究開発プログラムへの投資の増加
• 市場抑制要因
  • 皮下免疫グロブリン治療に伴う膨大なコスト
• 市場機会
  • 皮下免疫グロブリン治療に対する政府資金の増加と認知度の向上
  • 皮下免疫グロブリン投与における技術革新
• 市場の課題
  • 政府の厳しい規制と治療による副作用のリスクの高さ

ポーターの5つの力：皮下免疫グロブリン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：皮下免疫グロブリン市場における外部からの影響の把握

外部マクロ環境要因は、皮下免疫グロブリン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析皮下免疫グロブリン市場における競合情勢の把握

皮下免疫グロブリン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス皮下免疫グロブリン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、皮下免疫グロブリン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨皮下免疫グロブリン市場における成功への道筋を描く

皮下免疫グロブリン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 自己免疫疾患の有病率が世界的に上昇
    • 適応外適応症における皮下免疫グロブリンの使用増加
    • バイオテクノロジー企業と製薬企業による研究開発プログラムへの投資の増加
  • 抑制要因
    • 皮下免疫グロブリン治療に伴う莫大なコスト
  • 機会
    • 政府からの資金援助の増加と皮下免疫グロブリン治療の使用に関する意識の高まり
    • 皮下免疫グロブリンの管理における革新
  • 課題
    • 厳しい政府規制と治療の副作用リスクの高さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 皮下免疫グロブリン市場適応症別

• 原発性免疫不全症
• 二次免疫不全症

第7章 皮下免疫グロブリン市場：エンドユーザー別

• ホームケア設定
• 病院・クリニック

第8章 南北アメリカの皮下免疫グロブリン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の皮下免疫グロブリン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの皮下免疫グロブリン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Biotest AG by Grifols S.A.
• CSL Behring
• Kedrion Biopharma Inc.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• The Bio Products Laboratory

LIST OF FIGURES

• FIGURE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
• FIGURE 2. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SUBCUTANEOUS IMMUNOGLOBULIN MARKET DYNAMICS
• TABLE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 100. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023

The Subcutaneous Immunoglobulin Market was valued at USD 9.47 billion in 2023, expected to reach USD 10.46 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 19.46 billion by 2030.

Subcutaneous immunoglobulin (SCIg) refers to a medical therapy involving the administration of immunoglobulins via subcutaneous injection, primarily deployed in patients with primary immunodeficiency diseases and certain autoimmune disorders. Its necessity arises from the need to maintain adequate immunoglobulin levels, which are vital to fighting infections in patients with compromised immune systems. The application scope extends from regular home-based infusions, thereby offering patients greater convenience compared to intravenous routes, to hospital settings, primarily serving immunocompromised individuals. End-use segments include healthcare facilities, homecare settings, and specialty clinics. Market growth is significantly influenced by the rising prevalence of immunodeficiency disorders, advancements in SCIg formulations, and increasing patient preference for home-based treatments. Additionally, ongoing research and development yield innovative delivery mechanisms, such as needleless systems, which capture market attention. However, the market faces limitations from potential side effects, high costs of treatment, and regulatory challenges, which could hinder growth. Moreover, patient awareness regarding treatment options remains inconsistent across regions, adding to the challenges. The latest potential opportunities include expanding SCIg applications into new therapeutic areas and enhancing distribution networks to untapped markets. Recommendations to capture these opportunities include investment in education and awareness programs, partnerships with healthcare providers, and lobbying for favorable reimbursement policies. Innovations such as improving delivery devices and formulating more stable immunoglobulin preparations are promising areas of research for business growth. Furthermore, digital platforms for patient monitoring and management could present a strategic advantage. The SCIg market is characterized by a competitive landscape with several key players constantly investing in technological advancements. It requires strategic agility to navigate regulatory landscapes, patient advocacy, and competitive pressures while focusing on technological and therapeutic innovations for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Subcutaneous Immunoglobulin Market

The Subcutaneous Immunoglobulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the prevalence of autoimmune disorders globally
  • Increasing usage of subcutaneous immunoglobulin in off-label indications
  • Growing investments in R&D programs by biotechnology and pharmaceutical companies
• Market Restraints
  • Huge cost associated with subcutaneous immunoglobulin treatment
• Market Opportunities
  • Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
  • Innovations in the administration of subcutaneous immunoglobulin
• Market Challenges
  • Stringent government regulations and high risk of the side effects of the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Subcutaneous Immunoglobulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Subcutaneous Immunoglobulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Subcutaneous Immunoglobulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Subcutaneous Immunoglobulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Subcutaneous Immunoglobulin Market

A detailed market share analysis in the Subcutaneous Immunoglobulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Subcutaneous Immunoglobulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Subcutaneous Immunoglobulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Subcutaneous Immunoglobulin Market

A strategic analysis of the Subcutaneous Immunoglobulin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Subcutaneous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include Biotest AG by Grifols S.A., CSL Behring, Kedrion Biopharma Inc., Octapharma AG, Takeda Pharmaceutical Company Limited, and The Bio Products Laboratory.

Market Segmentation & Coverage

This research report categorizes the Subcutaneous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Primary Immunodeficiencies and Secondary Immunodeficiencies.
• Based on End-User, market is studied across Homecare Settings and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the prevalence of autoimmune disorders globally
    • 5.1.1.2. Increasing usage of subcutaneous immunoglobulin in off-label indications
    • 5.1.1.3. Growing investments in R&D programs by biotechnology and pharmaceutical companies
  • 5.1.2. Restraints
    • 5.1.2.1. Huge cost associated with subcutaneous immunoglobulin treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
    • 5.1.3.2. Innovations in the administration of subcutaneous immunoglobulin
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations and high risk of the side effects of the treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Subcutaneous Immunoglobulin Market, by Indication

• 6.1. Introduction
• 6.2. Primary Immunodeficiencies
• 6.3. Secondary Immunodeficiencies

7. Subcutaneous Immunoglobulin Market, by End-User

• 7.1. Introduction
• 7.2. Homecare Settings
• 7.3. Hospitals & Clinics

8. Americas Subcutaneous Immunoglobulin Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Subcutaneous Immunoglobulin Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Subcutaneous Immunoglobulin Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Biotest AG by Grifols S.A.
• 2. CSL Behring
• 3. Kedrion Biopharma Inc.
• 4. Octapharma AG
• 5. Takeda Pharmaceutical Company Limited
• 6. The Bio Products Laboratory